Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is ...

To find out more about sleep apnea masks, we spoke to Dr. Carlos Nunez, Physician and Chief Medical Officer at medical equipment manufacture ResMed. Here, he explains how useful sleep apnea masks ...

Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

ResMed beats estimates on strong sleep apnea device sales January 24, 2024 ResMed said its respiratory masks containing magnets will remain on the market even though the U.S. Food and Drug ...

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...